This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dova Receives Approval for Doptelet in Europe, Stock Up
by Zacks Equity Research
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Rigel Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
by Zacks Equity Research
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 5.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Rigel Pharmaceuticals (RIGL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 12.50% and 38.41%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug
by Zacks Equity Research
The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.
Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and 489.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why
by Zacks Equity Research
Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.
Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session
by Zacks Equity Research
Shares of Rigel Pharmaceuticals (RIGL) rose over 8% yesterday.
Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug
by Zacks Equity Research
Rigel's (RIGL) stock plunges 13% on the failure of a phase II study on lead drug, fostamatinib, in patients with IgA nephropathy (IgAN).
Options Traders Expect Huge Moves in Rigel Pharmaceuticals (RIGL) Stock
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) needs investors to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) needs investors to pay close attention to the stock based on moves in the options market lately.
Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
by Zacks Equity Research
Rigel Pharmaceuticals, Inc. (RIGL) announced that the FDA has accepted its new drug application (NDA) seeking approval for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
by Zacks Equity Research
Investors in Rigel Pharmaceuticals, Inc. (RIGL) need to pay close attention to the stock based on moves in the options market lately.
Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug
by Zacks Equity Research
Rigel Pharmaceuticals, Inc. (RIGL) recently announced that it has filed a new drug application (NDA) to the FDA, for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment immune thrombocytopenia (ITP).
5 Top Breakout Stocks to Boost Your Portfolio
by Swarup Gupta
If properly implemented, such a strategy could deliver impressive returns.
Increased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher?
by Zacks Equity Research
Rigel (RIGL) could be an interesting play for investors as it sees solid activity on the earnings estimate revision.
Will Rigel Pharmaceuticals (RIGL) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Rigel Pharmaceuticals, Inc. (RIGL).
5 Cheap Breakout Stocks for Superb Returns
by Swarup Gupta
The technique identifies those stocks whose prices are fluctuating within a specific band.
Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?
by Sanghamitra Saha
Inside the changes in portfolio constituents of two BioShares Biotech ETFs.